MyoKardia (MYOK) Tops Q4 EPS by 20c
Get Alerts MYOK Hot Sheet
Join SI Premium – FREE
MyoKardia (NASDAQ: MYOK) reported Q4 EPS of ($0.21), $0.20 better than the analyst estimate of ($0.41). Collaboration & License revenue for the quarter came in at $5.6 million versus the consensus estimate of $6.08 million.
For earnings history and earnings-related data on MyoKardia (MYOK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Volcon (VLCN) Reports 2023 Operational and Financial Results
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
- Sprinklr (CXM) Tops Q4 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!